Screen biomarkers of human lung squamous carcinoma by serological proteome analysis of HTB-182

Carcinogenesis of lung squamous carcinoma is a complex process involving multiple events and steps. At present, there are very few special lung cancer molecular markers for an “early-stage” diagnosis and prognosis evaluation. To identify tumor-associated antigens, serological proteome analysis (SERPA) of human lung squamous carcinoma cell line HTB-182 are performed. We characterized sixteen differentially expressed proteins which react with lung squamous carcinoma patient sera while not react with control sera. Some of these candidate lung squamous carcinoma-associated antigens were metabolic enzymes, such as triosephosphatase isomerase (TPIS). Some proteins were involved in the regulation of cell cycle and signal transduction. The results will provide scientific foundation for screening the molecular biomarkers used to diagnose and treat lung squamous carcinoma, as well as to elevate the patient's prognosis and provide new clue for the research of lung squamous carcinogenic mechanism. Thus, SERPA represents a valuable approach for the identification of differentially expressed proteins, which might be used as markers for the diagnosis and prognosis of lung squamous carcinoma.